GraniteShares 2x Long NVDA Daily ETF vs Revvity Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $36.91 (market cap $3.56B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 4.8× GraniteShares 2x Long NVDA Daily ETF's market cap, and Revvity Inc pays a 0.18% dividend while GraniteShares 2x Long NVDA Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and Revvity Inc for 12 Days on average.
| NVDL | RVTY | |
|---|---|---|
Market Cap | $3.56B | $16.98B |
Volume | 9,740,643 | 1,456,900 |
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $157.36 |
52-Week Low | $21.76 | $82.26 |
Typical Hold Time | 15 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
NVDL (GraniteShares 2x Long NVDA Daily ETF) trades at $36.905, down 6.73% on the day, with technical indicators showing a bullish bias from moving averages but neutral oscillators. The ETF provides 2x daily leveraged exposure to NVIDIA, which continues to lead AI innovation and recently beat Q2 2027 earnings estimates. Support levels are clustered around $36-$34, with resistance at $38-$41.
While leveraged exposure to NVIDIA's AI leadership offers significant upside potential, NVDL faces risks from daily reset mechanics that can cause performance drift from long-term NVDA returns. Recent articles highlight both optimism about NVIDIA's technical breakout and concerns about the ETF's tracking efficiency. The bullish technical setup suggests near-term opportunity, but volatility remains elevated.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →